Related Experiment Videos
Epstein-Barr virus and Burkitt's lymphoma worldwide: the causal relationship revisited
Insights
Epstein-Barr virus (EBV) is strongly linked to Burkitt's lymphoma (BL) globally. High EBV antibody levels predict BL risk, with malaria potentially increasing susceptibility through immune deficiency.
Area of Science:
- Oncology
- Virology
- Epidemiology
Background:
- Burkitt's lymphoma (BL) is the most common childhood cancer in tropical Africa, with a high association with Epstein-Barr virus (EBV).
- BL incidence and EBV association decrease from equatorial Africa to North Africa and Western countries.
- EBV is implicated in BL pathogenesis, with high antibody titers preceding tumor development.
Purpose of the Study:
- To investigate the global association between Epstein-Barr virus (EBV) and Burkitt's lymphoma (BL).
- To explore factors influencing BL development, including EBV infection and malaria.
- To assess the potential for EBV-targeted interventions in BL prevention.
Main Methods:
- Analysis of Burkitt's lymphoma incidence and EBV association across different global regions.
- Prospective study in Uganda correlating antibody titers to viral capsid antigen (VCA) with BL development.
- Investigation into the role of malaria in EBV-specific T-cell immune deficiency.
Main Results:
- A clear correlation exists between increasing BL incidence and higher EBV association from industrialized to equatorial regions.
- High VCA antibody titers years before diagnosis indicate increased BL risk.
- Malaria may promote BL through EBV-specific T-cell immune deficiency.
Conclusions:
- EBV plays a critical role in the majority of Burkitt's lymphoma cases worldwide.
- Early or massive EBV infection is a key event in equatorial Africa, while other factors contribute in other regions.
- Intervention against EBV could be a viable strategy for BL prevention.
Abstract:
Burkitt's lymphoma (BL) in tropical Africa represents by far the most common tumour in children between 0 and 14 years of age, 97% of the tumours being associated with Epstein-Barr virus (EBV). In North Africa, the tumour is about ten times less frequent than in equatorial Africa, but, according to reports from Algeria, 85% of the cases appear to be associated with EBV. In Western countries, BL represents about 3% of childhood tumours, 10 to 15% of them EBV-associated. Thus, from the northern industrialized countries to the equatorial developing countries, increasing incidences of lymphomas of the BL type are paralleled by an increasing proportion of EBV-associated cases. The Ugandan BL prospective study showed that high antibody titres to viral capsid antigen (VCA) preceded BL development by many years, with a quantifiable relationship between the level of VCA antibodies and tumour risk. If an early and/or massive EBV primary infection seems to represent the critical event for BL development in equatorial Africa, the favourable conditions for EBV-associated tumours in North Africa and in Europe remain to be investigated. Malaria appears to favour BL development through an EBV-specific T-cell immune deficiency. Chromosomal translocations and oncogene activation, considered as the final step in lymphoma development, do not appear to be related to EBV. Intervention against the virus may represent the ultimate proof of a causal relationship between EBV and the majority of BL cases around the world.